Compare SLNG & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | BMEA |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.2M | 107.7M |
| IPO Year | 2019 | 2021 |
| Metric | SLNG | BMEA |
|---|---|---|
| Price | $3.73 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $10.00 | $8.86 |
| AVG Volume (30 Days) | 75.5K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2400.00 | 69.19 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $68,245,000.00 | N/A |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $14.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.21 | $0.87 |
| 52 Week High | $6.36 | $3.07 |
| Indicator | SLNG | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 74.53 |
| Support Level | $3.25 | $1.77 |
| Resistance Level | $5.08 | $2.06 |
| Average True Range (ATR) | 0.53 | 0.14 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 22.29 | 98.81 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.